This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy of Ventavis Used in Real-life Setting. (SPHERA)

This study has been completed.
Information provided by (Responsible Party):
Bayer Identifier:
First received: May 17, 2011
Last updated: September 20, 2017
Last verified: September 2017

This is a registry of patients diagnosed with pulmonary arterial hypertension, scheduled for treatment with Ventavis.

Typical clinical measures and quality of life will be prospectively followed in 12 months period.

Condition Intervention
Pulmonary Arterial Hypertension Drug: Inhaled iloprost (Ventavis, BAYQ6256)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: The Efficacy of Inhaled Iloprost in Patients Treated Within the "Pulmonary Arterial Hypertension Therapeutic Programme".

Resource links provided by NLM:

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Changes of the exercise capacity as measured by 6-minutes walking distance [ Time Frame: 3, 6, 9 and 12 months vs. baseline ]

Secondary Outcome Measures:
  • Changes of depression score over time [ Time Frame: 3, 6, 9 and 12 months vs. baseline ]
  • Changes of functional capacity as measured by WHO classification system [ Time Frame: 3, 6, 9 and 12 months vs. baseline ]
  • Changes of pulmonary haemodynamics [ Time Frame: 3, 6, 9 and 12 months vs. baseline ]
  • Changes of serum level of natriuretic peptide B [ Time Frame: 3, 6, 9 and 12 months vs. baseline ]
  • Changes of Quality of Life score [ Time Frame: 3, 6, 9 and 12 months vs. baseline ]

Enrollment: 52
Actual Study Start Date: August 5, 2010
Study Completion Date: September 22, 2016
Primary Completion Date: April 28, 2016 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1
Drug (incl. Placebo)
Drug: Inhaled iloprost (Ventavis, BAYQ6256)
Patients treated with inhaled iloprost (Ventavis) 2.5 or 5 micrograms 6-9 times daily


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Adult patients prescribed Ventavis within the Pulmonary Arterial Hypertension Therapeutic Programme.

Inclusion Criteria:

  • Pulmonary arterial hypertension
  • Age 18+
  • Patients newly treated with Ventavis or switched from sildenafil

Exclusion Criteria:

  • Retrospective documentation is not allowed
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01355380

Many Locations, Poland
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer Identifier: NCT01355380     History of Changes
Other Study ID Numbers: 15308
VE1010PL ( Other Identifier: Company internal )
Study First Received: May 17, 2011
Last Updated: September 20, 2017

Keywords provided by Bayer:
Pulmonary arterial hypertension
Inhaled iloprost
Quality of life

Additional relevant MeSH terms:
Familial Primary Pulmonary Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Diseases
Platelet Aggregation Inhibitors
Vasodilator Agents processed this record on September 21, 2017